Corcept Therapeutics (CORT) Capital Expenditures (2016 - 2025)
Historic Capital Expenditures for Corcept Therapeutics (CORT) over the last 12 years, with Q2 2025 value amounting to $57000.0.
- Corcept Therapeutics' Capital Expenditures fell 8629.81% to $57000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $282000.0, marking a year-over-year decrease of 8625.06%. This contributed to the annual value of $2.2 million for FY2024, which is 146258.99% up from last year.
- Per Corcept Therapeutics' latest filing, its Capital Expenditures stood at $57000.0 for Q2 2025, which was down 8629.81% from $104000.0 recorded in Q1 2025.
- Corcept Therapeutics' Capital Expenditures' 5-year high stood at $1.6 million during Q3 2024, with a 5-year trough of $12000.0 in Q1 2022.
- Over the past 5 years, Corcept Therapeutics' median Capital Expenditures value was $104000.0 (recorded in 2025), while the average stood at $223600.0.
- In the last 5 years, Corcept Therapeutics' Capital Expenditures tumbled by 9047.62% in 2022 and then skyrocketed by 431891.89% in 2024.
- Over the past 5 years, Corcept Therapeutics' Capital Expenditures (Quarter) stood at $65000.0 in 2021, then crashed by 52.31% to $31000.0 in 2022, then rose by 19.35% to $37000.0 in 2023, then skyrocketed by 227.03% to $121000.0 in 2024, then plummeted by 52.89% to $57000.0 in 2025.
- Its last three reported values are $57000.0 in Q2 2025, $104000.0 for Q1 2025, and $121000.0 during Q4 2024.